Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study

François Barbier,Claire Dupuis,Niccolò Buetti,Carole Schwebel,Élie Azoulay,Laurent Argaud,Yves Cohen,Vivien Hong Tuan Ha,Marc Gainnier,Shidasp Siami,Jean-Marie Forel,Christophe Adrie,Étienne de Montmollin,Jean Reignier,Stéphane Ruckly,Jean-Ralph Zahar,Jean-François Timsit,the OutcomeRéa Study Group

DOI: https://doi.org/10.1186/s13054-023-04792-0

IF: 15.1

2024-01-06

Critical Care

Abstract:In this study including 391 critically ill patients with nosocomial pneumonia due to Gram-negative pathogens, combination therapy was not associated with a reduced hazard of death at Day 28 or a greater likelihood of clinical cure at Day 14. No over-risk of AKI was observed in patients receiving combination therapy.

critical care medicine

What problem does this paper attempt to address?

The paper primarily explores the effectiveness of monotherapy versus combination antimicrobial therapy in treating hospital-acquired pneumonia (HAP), ventilator-associated hospital-acquired pneumonia (vHAP), and ventilator-associated pneumonia (VAP) caused by Gram-negative pathogens. The specific objectives of the study include:

- **Primary Endpoint**: To assess the impact of initial appropriate combination antimicrobial therapy compared to monotherapy on the 28-day all-cause mortality rate in intensive care unit (ICU) patients.
- **Secondary Endpoints**: To evaluate the impact of combination therapy on the 14-day clinical cure rate and the composite endpoint of death or new-onset acute kidney injury (AKI) within 7 days.

### Study Methods

- **Study Design**: This is a retrospective multicenter cohort study based on prospectively collected data.
- **Study Population**: The study included 391 ICU patients with HAP, vHAP, or VAP caused by a single Gram-negative bacterium, who received initial appropriate monotherapy or combination antimicrobial therapy.
- **Interventions**: Patients were divided into a monotherapy group (151 patients) and a combination therapy group (240 patients).
- **Statistical Analysis**: The average effect of combination therapy on study endpoints was assessed using inverse probability weighting regression and multivariable regression models.

### Main Results

- **28-day All-Cause Mortality**: No significant difference was observed between the two groups (monotherapy group 28.5%, combination therapy group 32.9%; adjusted odds ratio [aOR] 1.14; 95% confidence interval [CI] 0.73–1.77; P=0.56).
- **14-day Clinical Cure Rate**: There was a slight trend towards lower clinical cure in the combination therapy group (monotherapy group 49.7%, combination therapy group 40.0%; aOR 0.79; 95% CI 0.53–1.20; P=0.27).
- **7-day Death or AKI**: No significant difference was observed between the two groups (aOR 1.07; 95% CI 0.71–1.63; P=0.73).

### Conclusion

For critically ill patients with HAP, vHAP, or VAP caused by Gram-negative bacteria, initial combination antimicrobial therapy did not show an independent impact on 28-day all-cause mortality, 14-day clinical cure rate, or the composite endpoint of death or AKI within 7 days compared to monotherapy.